NCT01189279

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. Two formulations of bimatoprost will be investigated in Part 1 and a third formulation of bimatoprost will be investigated in Part 2. Part 2 will begin after Part 1 has completed.

Conditions

• Alopecia
• Alopecia, Androgenetic
• Baldness

Interventions

Type	Name	Description
DRUG	bimatoprost Formulation A	bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
DRUG	bimatoprost Formulation B	bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
DRUG	bimatoprost Formulation C	bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-01-01
• Completion: 2011-02-01
• First posted: 2010-08-26
• Last updated: 2013-08-30
• Results posted: 2013-08-30

Locations

1 site across 1 country: United States